l carnosine Search Results


elution  (Gold Biotechnology Inc)
94
Gold Biotechnology Inc elution
Elution, supplied by Gold Biotechnology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/l+carnosine/N-Acetyl-L-carnosine/pmc09758054-263-0-45
Average 94 stars, based on 1 article reviews
elution - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
l carnosine  (MedChemExpress)
94
MedChemExpress l carnosine
L Carnosine, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/l+carnosine/L-Carnosine/pm42372708-71-4-43
Average 94 stars, based on 1 article reviews
l carnosine - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
polaprezinc  (MedChemExpress)
91
MedChemExpress polaprezinc
Suppression of CRPC tumor growth by PRDX5 inhibitors A) LNCaP epiDTP and enzDTP cell survivals were reduced by POL with IC 50 of 4.71 µM and 4.15 µM, and by STA with IC 50 of 4.08 µM and 3.82 µM, respectively. B) PRDX5 protein level was not changed by the treatment of POL, STA alone, or in combination with EPI, ENZ as measured by Western blotting. β‐ACTIN protein was used as the loading control. C) Cellular PRDX5 activity was measured by enzymatic assay in the presence of POL, STA, EPI, PRDX5 protein, or siPRDX5 alone or in combination. PRDX5 activity was inhibited by POL, STA, and siPRDX5, but increased by PRDX5 protein. D) Cell death rate (%) was measured by LDH release assay in the presence of POL, STA, EPI, PRDX5 protein, or siPRDX5 alone or in combination. Data are expressed as mean ± std of triplicates. One‐way ANOVA with the Turkey test was performed. p <0.05 was considered significant and indicated by different letters. E) PRDX5 inhibitor slowed down CRPC progression in mice. Weight and photograph of the prostate are shown from MYC T mice (6 per group) treated with enzalutamide (ENZ), abiraterone (ABI), <t>polaprezinc</t> (POL), stachyose (STA), or in combinations. AP: anterior prostate lobe, DL: dorsolateral prostate lobe, VP: ventral prostate lobe. Student's t ‐test was performed, ** and ***indicate p <0.01 and p <0.001, respectively. F) Representative images of prostate histopathology. Age and treatment are labeled.
Polaprezinc, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/l+carnosine/Polaprezinc/pmc10916659-154-15-16
Average 91 stars, based on 1 article reviews
polaprezinc - by Bioz Stars, 2026-10
91/100 stars
  Buy from Supplier
l carnosine  (Biosynth Carbosynth)
91
Biosynth Carbosynth l carnosine
Suppression of CRPC tumor growth by PRDX5 inhibitors A) LNCaP epiDTP and enzDTP cell survivals were reduced by POL with IC 50 of 4.71 µM and 4.15 µM, and by STA with IC 50 of 4.08 µM and 3.82 µM, respectively. B) PRDX5 protein level was not changed by the treatment of POL, STA alone, or in combination with EPI, ENZ as measured by Western blotting. β‐ACTIN protein was used as the loading control. C) Cellular PRDX5 activity was measured by enzymatic assay in the presence of POL, STA, EPI, PRDX5 protein, or siPRDX5 alone or in combination. PRDX5 activity was inhibited by POL, STA, and siPRDX5, but increased by PRDX5 protein. D) Cell death rate (%) was measured by LDH release assay in the presence of POL, STA, EPI, PRDX5 protein, or siPRDX5 alone or in combination. Data are expressed as mean ± std of triplicates. One‐way ANOVA with the Turkey test was performed. p <0.05 was considered significant and indicated by different letters. E) PRDX5 inhibitor slowed down CRPC progression in mice. Weight and photograph of the prostate are shown from MYC T mice (6 per group) treated with enzalutamide (ENZ), abiraterone (ABI), <t>polaprezinc</t> (POL), stachyose (STA), or in combinations. AP: anterior prostate lobe, DL: dorsolateral prostate lobe, VP: ventral prostate lobe. Student's t ‐test was performed, ** and ***indicate p <0.01 and p <0.001, respectively. F) Representative images of prostate histopathology. Age and treatment are labeled.
L Carnosine, supplied by Biosynth Carbosynth, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/l+carnosine/L-Carnosine/pmc08466808-31-0-8
Average 91 stars, based on 1 article reviews
l carnosine - by Bioz Stars, 2026-10
91/100 stars
  Buy from Supplier
l carnosine  (Thermo Fisher)
93
Thermo Fisher l carnosine
Suppression of CRPC tumor growth by PRDX5 inhibitors A) LNCaP epiDTP and enzDTP cell survivals were reduced by POL with IC 50 of 4.71 µM and 4.15 µM, and by STA with IC 50 of 4.08 µM and 3.82 µM, respectively. B) PRDX5 protein level was not changed by the treatment of POL, STA alone, or in combination with EPI, ENZ as measured by Western blotting. β‐ACTIN protein was used as the loading control. C) Cellular PRDX5 activity was measured by enzymatic assay in the presence of POL, STA, EPI, PRDX5 protein, or siPRDX5 alone or in combination. PRDX5 activity was inhibited by POL, STA, and siPRDX5, but increased by PRDX5 protein. D) Cell death rate (%) was measured by LDH release assay in the presence of POL, STA, EPI, PRDX5 protein, or siPRDX5 alone or in combination. Data are expressed as mean ± std of triplicates. One‐way ANOVA with the Turkey test was performed. p <0.05 was considered significant and indicated by different letters. E) PRDX5 inhibitor slowed down CRPC progression in mice. Weight and photograph of the prostate are shown from MYC T mice (6 per group) treated with enzalutamide (ENZ), abiraterone (ABI), <t>polaprezinc</t> (POL), stachyose (STA), or in combinations. AP: anterior prostate lobe, DL: dorsolateral prostate lobe, VP: ventral prostate lobe. Student's t ‐test was performed, ** and ***indicate p <0.01 and p <0.001, respectively. F) Representative images of prostate histopathology. Age and treatment are labeled.
L Carnosine, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/l+carnosine/L-Carnosine%2C+98%25/pmc12790938-150-35-40
Average 93 stars, based on 1 article reviews
l carnosine - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier
l carnosine  (Chem Impex International)
95
Chem Impex International l carnosine
Suppression of CRPC tumor growth by PRDX5 inhibitors A) LNCaP epiDTP and enzDTP cell survivals were reduced by POL with IC 50 of 4.71 µM and 4.15 µM, and by STA with IC 50 of 4.08 µM and 3.82 µM, respectively. B) PRDX5 protein level was not changed by the treatment of POL, STA alone, or in combination with EPI, ENZ as measured by Western blotting. β‐ACTIN protein was used as the loading control. C) Cellular PRDX5 activity was measured by enzymatic assay in the presence of POL, STA, EPI, PRDX5 protein, or siPRDX5 alone or in combination. PRDX5 activity was inhibited by POL, STA, and siPRDX5, but increased by PRDX5 protein. D) Cell death rate (%) was measured by LDH release assay in the presence of POL, STA, EPI, PRDX5 protein, or siPRDX5 alone or in combination. Data are expressed as mean ± std of triplicates. One‐way ANOVA with the Turkey test was performed. p <0.05 was considered significant and indicated by different letters. E) PRDX5 inhibitor slowed down CRPC progression in mice. Weight and photograph of the prostate are shown from MYC T mice (6 per group) treated with enzalutamide (ENZ), abiraterone (ABI), <t>polaprezinc</t> (POL), stachyose (STA), or in combinations. AP: anterior prostate lobe, DL: dorsolateral prostate lobe, VP: ventral prostate lobe. Student's t ‐test was performed, ** and ***indicate p <0.01 and p <0.001, respectively. F) Representative images of prostate histopathology. Age and treatment are labeled.
L Carnosine, supplied by Chem Impex International, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/l+carnosine/b-Ala-His-OH/pm35073071__ja1c11750_si_001-6-0-9
Average 95 stars, based on 1 article reviews
l carnosine - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier
l -carnosine  (Bachem)
90
Bachem l -carnosine
Suppression of CRPC tumor growth by PRDX5 inhibitors A) LNCaP epiDTP and enzDTP cell survivals were reduced by POL with IC 50 of 4.71 µM and 4.15 µM, and by STA with IC 50 of 4.08 µM and 3.82 µM, respectively. B) PRDX5 protein level was not changed by the treatment of POL, STA alone, or in combination with EPI, ENZ as measured by Western blotting. β‐ACTIN protein was used as the loading control. C) Cellular PRDX5 activity was measured by enzymatic assay in the presence of POL, STA, EPI, PRDX5 protein, or siPRDX5 alone or in combination. PRDX5 activity was inhibited by POL, STA, and siPRDX5, but increased by PRDX5 protein. D) Cell death rate (%) was measured by LDH release assay in the presence of POL, STA, EPI, PRDX5 protein, or siPRDX5 alone or in combination. Data are expressed as mean ± std of triplicates. One‐way ANOVA with the Turkey test was performed. p <0.05 was considered significant and indicated by different letters. E) PRDX5 inhibitor slowed down CRPC progression in mice. Weight and photograph of the prostate are shown from MYC T mice (6 per group) treated with enzalutamide (ENZ), abiraterone (ABI), <t>polaprezinc</t> (POL), stachyose (STA), or in combinations. AP: anterior prostate lobe, DL: dorsolateral prostate lobe, VP: ventral prostate lobe. Student's t ‐test was performed, ** and ***indicate p <0.01 and p <0.001, respectively. F) Representative images of prostate histopathology. Age and treatment are labeled.
L Carnosine, supplied by Bachem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/l+carnosine/l+carnosin/pmc06017309-82-13-18
Average 90 stars, based on 1 article reviews
l -carnosine - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
n-acetyl- l -carnosine  (Merck KGaA)
90
Merck KGaA n-acetyl- l -carnosine
Suppression of CRPC tumor growth by PRDX5 inhibitors A) LNCaP epiDTP and enzDTP cell survivals were reduced by POL with IC 50 of 4.71 µM and 4.15 µM, and by STA with IC 50 of 4.08 µM and 3.82 µM, respectively. B) PRDX5 protein level was not changed by the treatment of POL, STA alone, or in combination with EPI, ENZ as measured by Western blotting. β‐ACTIN protein was used as the loading control. C) Cellular PRDX5 activity was measured by enzymatic assay in the presence of POL, STA, EPI, PRDX5 protein, or siPRDX5 alone or in combination. PRDX5 activity was inhibited by POL, STA, and siPRDX5, but increased by PRDX5 protein. D) Cell death rate (%) was measured by LDH release assay in the presence of POL, STA, EPI, PRDX5 protein, or siPRDX5 alone or in combination. Data are expressed as mean ± std of triplicates. One‐way ANOVA with the Turkey test was performed. p <0.05 was considered significant and indicated by different letters. E) PRDX5 inhibitor slowed down CRPC progression in mice. Weight and photograph of the prostate are shown from MYC T mice (6 per group) treated with enzalutamide (ENZ), abiraterone (ABI), <t>polaprezinc</t> (POL), stachyose (STA), or in combinations. AP: anterior prostate lobe, DL: dorsolateral prostate lobe, VP: ventral prostate lobe. Student's t ‐test was performed, ** and ***indicate p <0.01 and p <0.001, respectively. F) Representative images of prostate histopathology. Age and treatment are labeled.
N Acetyl L Carnosine, supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/l+carnosine/l+carnosine/pmc07084589-81-31-37
Average 90 stars, based on 1 article reviews
n-acetyl- l -carnosine - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
1μm carnosine-d4  (CDN Isotopes)
90
CDN Isotopes 1μm carnosine-d4
Suppression of CRPC tumor growth by PRDX5 inhibitors A) LNCaP epiDTP and enzDTP cell survivals were reduced by POL with IC 50 of 4.71 µM and 4.15 µM, and by STA with IC 50 of 4.08 µM and 3.82 µM, respectively. B) PRDX5 protein level was not changed by the treatment of POL, STA alone, or in combination with EPI, ENZ as measured by Western blotting. β‐ACTIN protein was used as the loading control. C) Cellular PRDX5 activity was measured by enzymatic assay in the presence of POL, STA, EPI, PRDX5 protein, or siPRDX5 alone or in combination. PRDX5 activity was inhibited by POL, STA, and siPRDX5, but increased by PRDX5 protein. D) Cell death rate (%) was measured by LDH release assay in the presence of POL, STA, EPI, PRDX5 protein, or siPRDX5 alone or in combination. Data are expressed as mean ± std of triplicates. One‐way ANOVA with the Turkey test was performed. p <0.05 was considered significant and indicated by different letters. E) PRDX5 inhibitor slowed down CRPC progression in mice. Weight and photograph of the prostate are shown from MYC T mice (6 per group) treated with enzalutamide (ENZ), abiraterone (ABI), <t>polaprezinc</t> (POL), stachyose (STA), or in combinations. AP: anterior prostate lobe, DL: dorsolateral prostate lobe, VP: ventral prostate lobe. Student's t ‐test was performed, ** and ***indicate p <0.01 and p <0.001, respectively. F) Representative images of prostate histopathology. Age and treatment are labeled.
1μm Carnosine D4, supplied by CDN Isotopes, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/l+carnosine/l+carnosine+d4/pmc10971688-95-9-17
Average 90 stars, based on 1 article reviews
1μm carnosine-d4 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
l-carnosine  (NeoSystems Corp)
90
NeoSystems Corp l-carnosine
Suppression of CRPC tumor growth by PRDX5 inhibitors A) LNCaP epiDTP and enzDTP cell survivals were reduced by POL with IC 50 of 4.71 µM and 4.15 µM, and by STA with IC 50 of 4.08 µM and 3.82 µM, respectively. B) PRDX5 protein level was not changed by the treatment of POL, STA alone, or in combination with EPI, ENZ as measured by Western blotting. β‐ACTIN protein was used as the loading control. C) Cellular PRDX5 activity was measured by enzymatic assay in the presence of POL, STA, EPI, PRDX5 protein, or siPRDX5 alone or in combination. PRDX5 activity was inhibited by POL, STA, and siPRDX5, but increased by PRDX5 protein. D) Cell death rate (%) was measured by LDH release assay in the presence of POL, STA, EPI, PRDX5 protein, or siPRDX5 alone or in combination. Data are expressed as mean ± std of triplicates. One‐way ANOVA with the Turkey test was performed. p <0.05 was considered significant and indicated by different letters. E) PRDX5 inhibitor slowed down CRPC progression in mice. Weight and photograph of the prostate are shown from MYC T mice (6 per group) treated with enzalutamide (ENZ), abiraterone (ABI), <t>polaprezinc</t> (POL), stachyose (STA), or in combinations. AP: anterior prostate lobe, DL: dorsolateral prostate lobe, VP: ventral prostate lobe. Student's t ‐test was performed, ** and ***indicate p <0.01 and p <0.001, respectively. F) Representative images of prostate histopathology. Age and treatment are labeled.
L Carnosine, supplied by NeoSystems Corp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/l+carnosine/l+carnosine/pmc01809322-171-4-10
Average 90 stars, based on 1 article reviews
l-carnosine - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
l -carnosine  (FUJIFILM)
90
FUJIFILM l -carnosine
Suppression of CRPC tumor growth by PRDX5 inhibitors A) LNCaP epiDTP and enzDTP cell survivals were reduced by POL with IC 50 of 4.71 µM and 4.15 µM, and by STA with IC 50 of 4.08 µM and 3.82 µM, respectively. B) PRDX5 protein level was not changed by the treatment of POL, STA alone, or in combination with EPI, ENZ as measured by Western blotting. β‐ACTIN protein was used as the loading control. C) Cellular PRDX5 activity was measured by enzymatic assay in the presence of POL, STA, EPI, PRDX5 protein, or siPRDX5 alone or in combination. PRDX5 activity was inhibited by POL, STA, and siPRDX5, but increased by PRDX5 protein. D) Cell death rate (%) was measured by LDH release assay in the presence of POL, STA, EPI, PRDX5 protein, or siPRDX5 alone or in combination. Data are expressed as mean ± std of triplicates. One‐way ANOVA with the Turkey test was performed. p <0.05 was considered significant and indicated by different letters. E) PRDX5 inhibitor slowed down CRPC progression in mice. Weight and photograph of the prostate are shown from MYC T mice (6 per group) treated with enzalutamide (ENZ), abiraterone (ABI), <t>polaprezinc</t> (POL), stachyose (STA), or in combinations. AP: anterior prostate lobe, DL: dorsolateral prostate lobe, VP: ventral prostate lobe. Student's t ‐test was performed, ** and ***indicate p <0.01 and p <0.001, respectively. F) Representative images of prostate histopathology. Age and treatment are labeled.
L Carnosine, supplied by FUJIFILM, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/l+carnosine/l+carnosine/pmc01853133-45-28-30
Average 90 stars, based on 1 article reviews
l -carnosine - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
l -carnitine  (Hamari Chemicals)
90
Hamari Chemicals l -carnitine
Suppression of CRPC tumor growth by PRDX5 inhibitors A) LNCaP epiDTP and enzDTP cell survivals were reduced by POL with IC 50 of 4.71 µM and 4.15 µM, and by STA with IC 50 of 4.08 µM and 3.82 µM, respectively. B) PRDX5 protein level was not changed by the treatment of POL, STA alone, or in combination with EPI, ENZ as measured by Western blotting. β‐ACTIN protein was used as the loading control. C) Cellular PRDX5 activity was measured by enzymatic assay in the presence of POL, STA, EPI, PRDX5 protein, or siPRDX5 alone or in combination. PRDX5 activity was inhibited by POL, STA, and siPRDX5, but increased by PRDX5 protein. D) Cell death rate (%) was measured by LDH release assay in the presence of POL, STA, EPI, PRDX5 protein, or siPRDX5 alone or in combination. Data are expressed as mean ± std of triplicates. One‐way ANOVA with the Turkey test was performed. p <0.05 was considered significant and indicated by different letters. E) PRDX5 inhibitor slowed down CRPC progression in mice. Weight and photograph of the prostate are shown from MYC T mice (6 per group) treated with enzalutamide (ENZ), abiraterone (ABI), <t>polaprezinc</t> (POL), stachyose (STA), or in combinations. AP: anterior prostate lobe, DL: dorsolateral prostate lobe, VP: ventral prostate lobe. Student's t ‐test was performed, ** and ***indicate p <0.01 and p <0.001, respectively. F) Representative images of prostate histopathology. Age and treatment are labeled.
L Carnitine, supplied by Hamari Chemicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/l+carnosine/l+carnosine/pm16967760-47-11-16
Average 90 stars, based on 1 article reviews
l -carnitine - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

Image Search Results


Suppression of CRPC tumor growth by PRDX5 inhibitors A) LNCaP epiDTP and enzDTP cell survivals were reduced by POL with IC 50 of 4.71 µM and 4.15 µM, and by STA with IC 50 of 4.08 µM and 3.82 µM, respectively. B) PRDX5 protein level was not changed by the treatment of POL, STA alone, or in combination with EPI, ENZ as measured by Western blotting. β‐ACTIN protein was used as the loading control. C) Cellular PRDX5 activity was measured by enzymatic assay in the presence of POL, STA, EPI, PRDX5 protein, or siPRDX5 alone or in combination. PRDX5 activity was inhibited by POL, STA, and siPRDX5, but increased by PRDX5 protein. D) Cell death rate (%) was measured by LDH release assay in the presence of POL, STA, EPI, PRDX5 protein, or siPRDX5 alone or in combination. Data are expressed as mean ± std of triplicates. One‐way ANOVA with the Turkey test was performed. p <0.05 was considered significant and indicated by different letters. E) PRDX5 inhibitor slowed down CRPC progression in mice. Weight and photograph of the prostate are shown from MYC T mice (6 per group) treated with enzalutamide (ENZ), abiraterone (ABI), polaprezinc (POL), stachyose (STA), or in combinations. AP: anterior prostate lobe, DL: dorsolateral prostate lobe, VP: ventral prostate lobe. Student's t ‐test was performed, ** and ***indicate p <0.01 and p <0.001, respectively. F) Representative images of prostate histopathology. Age and treatment are labeled.

Journal: Advanced Science

Article Title: Identification of PRDX5 as A Target for The Treatment of Castration‐Resistant Prostate Cancer

doi: 10.1002/advs.202304939

Figure Lengend Snippet: Suppression of CRPC tumor growth by PRDX5 inhibitors A) LNCaP epiDTP and enzDTP cell survivals were reduced by POL with IC 50 of 4.71 µM and 4.15 µM, and by STA with IC 50 of 4.08 µM and 3.82 µM, respectively. B) PRDX5 protein level was not changed by the treatment of POL, STA alone, or in combination with EPI, ENZ as measured by Western blotting. β‐ACTIN protein was used as the loading control. C) Cellular PRDX5 activity was measured by enzymatic assay in the presence of POL, STA, EPI, PRDX5 protein, or siPRDX5 alone or in combination. PRDX5 activity was inhibited by POL, STA, and siPRDX5, but increased by PRDX5 protein. D) Cell death rate (%) was measured by LDH release assay in the presence of POL, STA, EPI, PRDX5 protein, or siPRDX5 alone or in combination. Data are expressed as mean ± std of triplicates. One‐way ANOVA with the Turkey test was performed. p <0.05 was considered significant and indicated by different letters. E) PRDX5 inhibitor slowed down CRPC progression in mice. Weight and photograph of the prostate are shown from MYC T mice (6 per group) treated with enzalutamide (ENZ), abiraterone (ABI), polaprezinc (POL), stachyose (STA), or in combinations. AP: anterior prostate lobe, DL: dorsolateral prostate lobe, VP: ventral prostate lobe. Student's t ‐test was performed, ** and ***indicate p <0.01 and p <0.001, respectively. F) Representative images of prostate histopathology. Age and treatment are labeled.

Article Snippet: Enzalutamide (MCE, HY‐70002, NJ, US), EPI‐001 (Selleck, S7955, TX, US), Auranofin (MCE, HY‐B1123, NJ, US), Polaprezinc (MCE, HY‐B0729, NJ, US) and Darolutamide (Selleck, S7559, TX, US) were stored as stock solutions in DMSO (Sigma, MO, US).

Techniques: Western Blot, Control, Activity Assay, Enzymatic Assay, Lactate Dehydrogenase Assay, Histopathology, Labeling